LLY241213P735000
- 0.41
- +0.03+7.89%
Eli Lilly and Co Newsroom
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
Has Eli Lilly and Co's tirzepatide "defeated" Novo-Nordisk A/S's semaglutide? The competition for weight loss drugs is moving towards "precision breakthroughs."
Industry experts point out that the competition for weight loss drugs is no longer just about rapid weight loss, but requires a "targeted breakthrough" in safety and sustainability aspects, such as reducing weight regain, minimizing muscle loss, increasing medication convenience, and reducing side effects.
Why Eli Lilly and Company (LLY) Is the Best Safe Stock to Buy According to Analysts?
3 Stocks to Keep an Eye on After Dividend Hike Announcement
Xi'an Global Printing (002799.SZ): Has maintained a good cooperative relationship with Eli Lilly and Co and Novo-Nordisk A/S.
Gelonghui reported on December 12 that Xi'an Global Printing (002799.SZ) stated on the investor interaction platform that the company has maintained a good cooperative relationship with Eli Lilly and Co, Novo-Nordisk A/S, and other enterprises. In the future, the company will continue to strengthen market development efforts and expand its customer base.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900
Swiss Market Index Recovers Ahead of Interest Rate Decision
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's
Eli Lilly Ties Up With Ro to Improve Availability of Weight-Loss Drug Zepbound in Vials
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $997
Eli Lilly Unusual Options Activity
Eli Lilly Says Imlunestrant Improved Progression-Free Survival in Phase 3 Breast Cancer Study
Express News | Ro Works With Lilly to Streamline Patient Access to Authentic Zepbound Single-Dose Vials by Integrating With Lilly's Pharmacy Channel
Express News | Lilly's Imlunestrant, an Oral Serd, Significantly Improved Progression-Free Survival as Monotherapy and in Combination With Verzenio® (Abemaciclib) in Patients With Er+, Her2- Advanced Breast Cancer
Eli Lilly and Co will conduct research on whether weight loss drugs can effectively control addictive behavior.
On December 11, Glonghui reported that Eli Lilly and Co's CEO Dave Ricks stated that the company will begin studying whether its best-selling weight loss drug can also effectively control addiction behaviors such as alcoholism, smoking, and drug use. Ricks mentioned in a meeting that these medications are 'antidotes to pleasure' and may temporarily free patients from dependence on drugs. Some doctors have already indicated that this drug can help alleviate drug addiction. Novo-Nordisk A/S also indicated earlier this year that it plans to research drug addiction.
Express News | Ro: Vials to Be Available With on-Label Prescription From a Ro-Affiliated Provider via Integration With Lillydirect Self-Pay Pharmacy Channel
Lilly Is Launching a Lower-Cost Zepbound on Telehealth Site Ro
Bank of America: Resuming coverage of Eli Lilly and Co, rating it as 'Buy'.
Bank of America resumes coverage on Eli Lilly and Co, assigning a "Buy" rating with a Target Price of $997.